Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Clinical and genomic characterization of KRAS G13X non-small cell lung carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Targeting KRAS mutant in non-small cell lung cancer: Novel insights into therapeutic strategies
10.3389/fonc.2022.796832 · 2022 · External reference
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
10.1016/j.xcrm.2020.100186 · 2021 · External reference
Drugging KRAS: Current perspectives and state-of-art review
10.1186/s13045-022-01375-4 · 2022 · External reference
The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients
10.1158/2159-8290.cd-19-1167 · 2020 · External reference
KRAS G12C-mutant non-small cell lung cancer: Biology, developmental therapeutics, and molecular testing
10.1016/j.jmoldx.2021.02.002 · 2021 · External reference
KRAS G12C mutations in NSCLC: From target to resistance
10.3390/cancers13112541 · 2021 · External reference
Prognostic impact of KRAS-TP53 co-mutations in patients with early-stage non-small cell lung cancer: A single-center retrospective study
10.3390/jcm14145135 · 2025 · External reference
Impact of KRAS and TP53 co-mutations on outcomes after first-line systemic therapy among patients with STK11-mutated advanced non-small-cell lung cancer
10.1200/po.18.00326 · 2019 · External reference
A critical review of the prognostic and predictive implications of KRAS and STK11 mutations and co-mutations in metastatic non-small lung cancer
10.3390/jpm13061010 · 2023 · External reference
Characterization of KRAS mutation subtypes in non-small cell lung cancer
10.1158/1535-7163.mct-21-0201 · 2021 · External reference
Real-world outcomes of non-small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
10.1016/j.lungcan.2025.108421 · 2025 · External reference
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
10.1016/j.lungcan.2019.05.015 · 2019 · External reference
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS(G12D)-mutated non-small-cell lung cancer
10.1016/j.annonc.2022.07.005 · 2022 · External reference
Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant NSCLC
10.1016/j.jtocrr.2022.100390 · 2022 · External reference
Outcomes of patients with advanced NSCLC from the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France study by KRAS mutation subtypes
10.1016/j.jtocrr.2020.100052 · 2020 · External reference
Clinical characteristic and outcomes of KRAS G13 mutant non-small cell lung cancers
10.1200/jco.2022.40.16_suppl.e21017 · 2022 · External reference
Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer
10.1126/sciadv.abi9533 · 2022 · External reference
Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development
10.1073/pnas.2107599119 · 2022 · External reference
Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
10.1016/j.jtho.2021.10.013 · 2022 · External reference
TERT mutations in non-small cell lung cancer: Clinicopathologic features and prognostic implications
10.1177/11795549221140781 · 2023 · External reference
